Launching September 15, 2026. Join the waitlist
Velri

Medications/Weight

47 states + D.C. · Cash-pay

Tirzepatide Microdosing

Billed at the pharmacy's cost, if prescribed
  • A lower-dose tirzepatide program some people explore with a clinician as part of a weight goal.
  • Compounded, not FDA approved.

Velri opens September 15, 2026. A prescription is not guaranteed.

Tirzepatide Microdosing
Weight
Tirzepatide Microdosing
FormInjectable (multi-dose vial) + syringes
Dispensed byAn independent licensed pharmacy, if prescribed
DosingProvider-guided dosing
Compounded medications are not FDA approved.
Compounded medications are prepared by a licensed pharmacy for one patient, are not FDA approved, and are not interchangeable with a brand-name drug.
Illustrative. The pharmacy's packaging may differ. A prescription is never guaranteed.
Who prescribes, who dispenses
Prescribed by
An independent, physician-led Provider Group licensed in your state: TMD of CA PC · Online Medical Care P.C. · TMD of Kansas P.A. · TMD of Texas P.A..
Dispensed by
A licensed U.S. pharmacy, if prescribed.
Velri
Coordinates the membership, routing and follow-up. Velri does not prescribe, does not dispense, and adds no markup; one flat fulfillment fee per order, about $25.
A prescription is required and is never guaranteed. You may opt out of a given Provider Group or pharmacy at any time from your account.
Details
  • GoalWeight
  • FormInjectable (multi-dose vial) + syringes
  • OptionsLower-dose program. Formulation and dosing individualized by the prescribing provider
  • AvailabilityAvailability varies by state and pharmacy.
  • CostThe pharmacy’s cost, billed separately if prescribed. Velri adds no markup; one flat fulfillment fee per order, about $25.
What you pay
Velri membershipCoordination + support, billed by Velri$79/mo founding
Tirzepatide MicrodosingPer order, if prescribed. Velri adds no markup.pharmacy cost
Provider consultationOne-time, paid to an independent Provider Groupbilled separately
Safety & disclosures

The most common side effects are nausea, vomiting, diarrhea, decreased appetite, and constipation, most often around dose increases. Tirzepatide caused thyroid C-cell tumors in animal studies, and it must not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It has also been associated with pancreatitis, gallbladder disease, and kidney injury from severe dehydration, and taking it with insulin or a sulfonylurea increases the risk of low blood sugar. Do not use tirzepatide during pregnancy, and be aware it can make oral birth control pills less effective for a period after starting or increasing the dose. Seek emergency care for severe, persistent abdominal pain, with or without vomiting, which can be a sign of pancreatitis, and contact your provider promptly about a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath.

Compounded medications are not FDA approved. A prescription is required, is not guaranteed, and is determined by an independent, licensed provider based on your consultation. Velri is a non-clinical company; consultations and prescriptions are provided by independent, licensed Provider Groups, and medications are dispensed by independent, licensed pharmacies. Medication is priced at the pharmacy cost plus one flat Velri fulfillment fee, the same on every product. This page is for general information and is not medical advice.